• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Why Mali joined the ANTICOV clinical trial: A conversation with Dr Samba Sow

Home > Stories

Why Mali joined the ANTICOV clinical trial: A conversation with Dr Samba Sow

Microscope and lab equipment
28 Jun 2021

Early June, Mali enrolled its first patient in the ANTICOV clinical trial, a pan-African collaborative scientific study whose objective is to find treatments that can prevent mild-to-moderate COVID-19 cases from becoming severe.

Dr Samba SowThe Principal Investigator of the ANTICOV trial in Mali is Dr Samba Sow. He is a medical doctor, epidemiologist and Director of the Centre pour les Vaccins en Développement (CVD-Mali) du Ministère de la Santé du Mali, a public organization doing research and training on infectious diseases.

Dr Sow is a widely-recognized public health authority in the region: he was Minister of Health and Public Hygiene for Mali from 2017 to 2019 and was appointed in 2020 WHO Special envoy for COVID-19 in West Africa.

Dr Sow, what is the impact of the COVID-19 pandemic in Mali right now, in June 2021?

It is having a huge impact, not only in our daily lives but also on the delivery of primary care and on our healthcare system – which were already under major stress. We were not ready for such an emergency. Key health care activities such as maternal and child health, prenatal visits, childbirth, etc., delivery of treatments for tuberculosis, HIV, leprosy, malaria, or national programmes such as the one against blindness have been disrupted.

The repercussions on public health will be frightening and I am very worried for the future. To rebuild our healthcare system, it will require lots of time, efforts, energy, and collaborations.

I am also concerned by the attitude of many Malians, who seem to think that since vaccines now exist, the pandemic is over. The exact contrary is happening – it is getting worse. An aggravating factor is that our screening and pandemic surveillance activities are not working properly, which means we have trouble to evaluate the epidemiological situation.

What should be Mali’s answer to this massive public health crisis?

We need to open as many collaborations as possible. In the global fight against infectious diseases, a country can never go alone. Even a continent cannot go alone. The answer should be global. This is why ANTICOV is so important.

Even the most remote places, from every corner of the world, must join this global effort as early as possible, from the research phase, to become part of the solution. This is what my own country, Mali, must do.

We can see that vaccine research, for example, started in countries with high incomes and that this effort converted very fast into public health responses. The more deeply a country is involved in medical research, the easier it is to rapidly develop a response – because the results from this research are informing recommendations, policies, and public health decisions. If you do not conduct research from the start, you end up at the back of the queue. This is why Mali joined ANTICOV.

Could you explain your role in the ANTICOV trial?

I am the principal investigator, which means I am in charge of following, coordinating, and supervising all scientific, technical, administrative, and communication activities of the trial. A principal investigator is a linchpin of the trial and must spend a lot of time on the field, to work with his team and talk to the communities. A principal investigator cannot do anything without a strong team, and I am lucky to have one! Approximately 40 people are working directly on the ANTICOV trial in Mali.

‘In the global fight against infectious diseases, a country can never go alone. The answer should be global. This is why ANTICOV is so important.’

Dr Samba Sow

What are your expectations for the trial?

It is critical that ANTICOV succeeds. A success will be crucial for Mali and for all Africa – not only for the 13 participating countries.

ANTICOV’s objective is to find treatments for mild to moderate cases of COVID. These  are the most frequent cases we are seeing, and they are fuelling most community transmission. The number of beds in intensive care units in Mali is very limited, which means we must cure patients before their symptoms become severe. This is why this study is important.

Today, when we are talking treatments or vaccines, Africa is not in a good position. It is very important that Africans and African research organizations join the global effort to conduct trials.

How you do gain trust with your communities, to ensure that they will participate in the trial?

This is a very important question.  Without communities’ trust and support, even with the best study protocol of the world, you will go nowhere.

Fortunately, at the CVD-Mali, we are working closely and very early on with communities: we discuss with them the trial protocols as soon as they are approved. In every village, neighbourhood, or ‘commune’ we meet with representatives such as traditional or religious leaders, presidents of cultural, youth or women associations, etc.

Sometimes, during those meetings, people express doubts and have difficult questions. So we open our labs to them, we show them what we do with the samples we collected, we explain them the drugs we will distribute. These are truly transparency operations.

This is how we can convince communities that they will be the first to benefit from the research we do with them.

Photo credit: Kenny Mbala-DNDi, CVD-Mali

Pandemic Preparedness Africa

Read, watch, share

Loading...
Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

Stories
16 Apr 2025

Drug discovery explained: Chagas – How to prove treatments work?

Statements
16 Apr 2025

Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License